Cargando…
Five-year prognostic significance of global longitudinal strain in individuals with a hypertrophic cardiomyopathy gene mutation without hypertrophic changes
BACKGROUND: Previous studies have reported that global longitudinal strain (GLS) is reduced in patients with hypertrophic cardiomyopathy (HCM) while left ventricular ejection fraction (LVEF) is normal. Our aim was to assess GLS in individuals with HCM mutations without hypertrophic changes and to de...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bohn Stafleu van Loghum
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6393574/ https://www.ncbi.nlm.nih.gov/pubmed/30680638 http://dx.doi.org/10.1007/s12471-019-1226-5 |
_version_ | 1783398721692631040 |
---|---|
author | van Velzen, H. G. Schinkel, A. F. L. van Grootel, R. W. J. van Slegtenhorst, M. A. van der Velden, J. Strachinaru, M. Michels, M. |
author_facet | van Velzen, H. G. Schinkel, A. F. L. van Grootel, R. W. J. van Slegtenhorst, M. A. van der Velden, J. Strachinaru, M. Michels, M. |
author_sort | van Velzen, H. G. |
collection | PubMed |
description | BACKGROUND: Previous studies have reported that global longitudinal strain (GLS) is reduced in patients with hypertrophic cardiomyopathy (HCM) while left ventricular ejection fraction (LVEF) is normal. Our aim was to assess GLS in individuals with HCM mutations without hypertrophic changes and to determine its prognostic value for the development of HCM. METHODS AND RESULTS: This retrospective case-control and cohort study included 120 HCM mutation carriers and 110 controls. GLS and LVEF were assessed with Tomtec Imaging software. Age, gender, and body surface area were similar in mutation carriers and controls. Compared to controls, mutation carriers had a higher maximal wall thickness (9 ± 2 vs 8 ± 2 mm, p < 0.001), higher LVEF (60 ± 5 vs 58 ± 4%, p < 0.001) and higher GLS (−21.4 ± 2.3% vs −20.3 ± 2.2%, p < 0.001). The GLS difference was observed in the mid-left ventricle (−21.5 ± 2.5% vs −19.9 ± 2.5%, p < 0.001) and the apex (−24.1 ± 3.5% vs −22.1 ± 3.4%, p < 0.001), but not in the base of the left ventricle (−20.0 ± 3.3% vs −20.0 ± 2.6%, p = 0.9). Echocardiographic follow-up was performed in 80 mutation carriers. During 5.6 ± 2.9 years’ follow-up, 13 (16%) mutation carriers developed HCM. Cox regression analysis showed age (hazard ratio (HR) 1.08, p = 0.01), pathological Q wave (HR 8.56; p = 0.01), and maximal wall thickness (HR 1.94; p = 0.01) to be independent predictors of the development of HCM. GLS was not predictive of the development of HCM (HR 0.78, p = 0.07). CONCLUSION: GLS is increased in HCM mutation carriers without hypertrophic changes. GLS was of no clear prognostic value for the development of HCM during follow-up, in contrast to age, pathological Q waves and maximal wall thickness. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s12471-019-1226-5) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6393574 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Bohn Stafleu van Loghum |
record_format | MEDLINE/PubMed |
spelling | pubmed-63935742019-03-15 Five-year prognostic significance of global longitudinal strain in individuals with a hypertrophic cardiomyopathy gene mutation without hypertrophic changes van Velzen, H. G. Schinkel, A. F. L. van Grootel, R. W. J. van Slegtenhorst, M. A. van der Velden, J. Strachinaru, M. Michels, M. Neth Heart J Original Article BACKGROUND: Previous studies have reported that global longitudinal strain (GLS) is reduced in patients with hypertrophic cardiomyopathy (HCM) while left ventricular ejection fraction (LVEF) is normal. Our aim was to assess GLS in individuals with HCM mutations without hypertrophic changes and to determine its prognostic value for the development of HCM. METHODS AND RESULTS: This retrospective case-control and cohort study included 120 HCM mutation carriers and 110 controls. GLS and LVEF were assessed with Tomtec Imaging software. Age, gender, and body surface area were similar in mutation carriers and controls. Compared to controls, mutation carriers had a higher maximal wall thickness (9 ± 2 vs 8 ± 2 mm, p < 0.001), higher LVEF (60 ± 5 vs 58 ± 4%, p < 0.001) and higher GLS (−21.4 ± 2.3% vs −20.3 ± 2.2%, p < 0.001). The GLS difference was observed in the mid-left ventricle (−21.5 ± 2.5% vs −19.9 ± 2.5%, p < 0.001) and the apex (−24.1 ± 3.5% vs −22.1 ± 3.4%, p < 0.001), but not in the base of the left ventricle (−20.0 ± 3.3% vs −20.0 ± 2.6%, p = 0.9). Echocardiographic follow-up was performed in 80 mutation carriers. During 5.6 ± 2.9 years’ follow-up, 13 (16%) mutation carriers developed HCM. Cox regression analysis showed age (hazard ratio (HR) 1.08, p = 0.01), pathological Q wave (HR 8.56; p = 0.01), and maximal wall thickness (HR 1.94; p = 0.01) to be independent predictors of the development of HCM. GLS was not predictive of the development of HCM (HR 0.78, p = 0.07). CONCLUSION: GLS is increased in HCM mutation carriers without hypertrophic changes. GLS was of no clear prognostic value for the development of HCM during follow-up, in contrast to age, pathological Q waves and maximal wall thickness. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s12471-019-1226-5) contains supplementary material, which is available to authorized users. Bohn Stafleu van Loghum 2019-01-24 2019-03 /pmc/articles/PMC6393574/ /pubmed/30680638 http://dx.doi.org/10.1007/s12471-019-1226-5 Text en © The Author(s) 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Article van Velzen, H. G. Schinkel, A. F. L. van Grootel, R. W. J. van Slegtenhorst, M. A. van der Velden, J. Strachinaru, M. Michels, M. Five-year prognostic significance of global longitudinal strain in individuals with a hypertrophic cardiomyopathy gene mutation without hypertrophic changes |
title | Five-year prognostic significance of global longitudinal strain in individuals with a hypertrophic cardiomyopathy gene mutation without hypertrophic changes |
title_full | Five-year prognostic significance of global longitudinal strain in individuals with a hypertrophic cardiomyopathy gene mutation without hypertrophic changes |
title_fullStr | Five-year prognostic significance of global longitudinal strain in individuals with a hypertrophic cardiomyopathy gene mutation without hypertrophic changes |
title_full_unstemmed | Five-year prognostic significance of global longitudinal strain in individuals with a hypertrophic cardiomyopathy gene mutation without hypertrophic changes |
title_short | Five-year prognostic significance of global longitudinal strain in individuals with a hypertrophic cardiomyopathy gene mutation without hypertrophic changes |
title_sort | five-year prognostic significance of global longitudinal strain in individuals with a hypertrophic cardiomyopathy gene mutation without hypertrophic changes |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6393574/ https://www.ncbi.nlm.nih.gov/pubmed/30680638 http://dx.doi.org/10.1007/s12471-019-1226-5 |
work_keys_str_mv | AT vanvelzenhg fiveyearprognosticsignificanceofgloballongitudinalstraininindividualswithahypertrophiccardiomyopathygenemutationwithouthypertrophicchanges AT schinkelafl fiveyearprognosticsignificanceofgloballongitudinalstraininindividualswithahypertrophiccardiomyopathygenemutationwithouthypertrophicchanges AT vangrootelrwj fiveyearprognosticsignificanceofgloballongitudinalstraininindividualswithahypertrophiccardiomyopathygenemutationwithouthypertrophicchanges AT vanslegtenhorstma fiveyearprognosticsignificanceofgloballongitudinalstraininindividualswithahypertrophiccardiomyopathygenemutationwithouthypertrophicchanges AT vanderveldenj fiveyearprognosticsignificanceofgloballongitudinalstraininindividualswithahypertrophiccardiomyopathygenemutationwithouthypertrophicchanges AT strachinarum fiveyearprognosticsignificanceofgloballongitudinalstraininindividualswithahypertrophiccardiomyopathygenemutationwithouthypertrophicchanges AT michelsm fiveyearprognosticsignificanceofgloballongitudinalstraininindividualswithahypertrophiccardiomyopathygenemutationwithouthypertrophicchanges |